- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03332056
The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain (B&O)
The Use of Belladonna and Opium (B&O) Suppository in the Treatment of Postoperative Stent Pain: A Randomized, Double-Blinded Control Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose: Nephrolithiasis has an incidence of 10-15% in the US with 66% of practicing urologists placing a ureteral stent after each procedure. Ureteral stents are commonly placed to prevent or alleviate ureteral obstruction and ureteral stents are not well tolerated with up to 80% of patients reporting stent discomfort. These symptoms include urinary frequency, urgency, dysuria and incomplete emptying. Patients also frequently report suprapubic pain, hematuria and incontinence. Ureteral stents are placed either alone or in conjunction with other surgeries where ureteral access is obtained.
To date, however, there is no convincing data that altering stent characteristics or the use of a single drug dramatically improves stent discomfort for patients. Prior studies on oral therapies including alpha blockers and anti-muscarinics have shown some promise in improving stent comfort, however, they are typically used after the ureteral stent is placed and the patient has recovered from anesthesia. Other studies have shown no difference in stent symptoms in these two classes of drugs.
The Belladonna and Opium (B&O) suppository is a potent anti-muscarinic medication with narcotic properties. It frequently is used as a second line drug for patients with severe bladder spasms refractory to first line anti-muscarinic and narcotic medications from an indwelling Foley catheter or ureteral stent. It has shown efficacy for Foley catheter discomfort in patients undergoing robotic prostatectomies, but its use in the perioperative period has not been studied for ureteral stent discomfort.
The purpose of this study is to determine if preemptive B&O suppository placement will decrease post-operative pain in patients undergoing ureteral stent placement.
Procedures: The study is a randomized double-blind controlled trial comparing the use of a B&O suppository versus placebo suppository for the preemptive treatment of ureteral stent discomfort. 70 subjects will be recruited from the outpatient urologic clinic under the care of a single surgeon with appropriate informed consent. At the time of recruitment, patients will complete a validated AUA symptom score questionnaire in order to establish baseline symptom scores and urinary bother. Patients will be randomized into a treatment arm or a placebo arm. Those randomized to the treatment arm will receive a single B&O suppository, dose-weight calculated, immediately following patient positioning prior to instrumentation. Those randomized to the other arm will receive a single placebo suppository. The suppository will be administered by the circulating operative nurse and the remainder of the surgical team will be blinded to the study drug. Following treatment and stent placement, all patients will receive standard post-operative pain management (hydrocodone/acetaminophen, docusate, and tamsulosin) with usual discharge instructions.
Subject Population: Primary study population is patients who will receive ureteroscopy with concurrent placement of a ureteral stent. Primary exclusion criteria include age < 18, neurologic deficits of any kind and non-English speaking patients.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients who will receive ureteroscopy with concurrent placement of a ureteral stent.
Exclusion Criteria:
- age < 18,
- neurologic deficits of any kind
- non-English speaking patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Belladonna and Opium (B&O) suppository
A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation.
The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine.
Opium is compound drug that is composed of 20 alkaloids.
The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
|
Other Names:
|
Placebo Comparator: Placebo Suppository
placebo suppository
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Quality of Life Score on Postoperative Day 1
Time Frame: postoperative day 1
|
Global quality of life score as measured by the Ureteral Stent Symptom Questionnaire (USSQ). Scale is 1-7 (Lower score indicating better quality of life compared to higher score). 1 = delighted, 2 = pleased, 3 = mostly satisfied, 4 = mixed feelings (about equally satisfied and dissatisfied), 5 = mostly dissatisfied, 6 = unhappy, 7 = terrible |
postoperative day 1
|
Global Quality of Life Score on Postoperative 3
Time Frame: postoperative day 3
|
Global quality of life score as measured by the Ureteral Stent Symptom Questionnaire (USSQ). Scale is 1-7 (Lower score indicating better quality of life compared to higher score). 1 = delighted, 2 = pleased, 3 = mostly satisfied, 4 = mixed feelings (about equally satisfied and dissatisfied), 5 = mostly dissatisfied, 6 = unhappy, 7 = terrible |
postoperative day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Postoperative Complications as a Result of the Use of B&O Suppository
Time Frame: 14 days post-op
|
To assess postoperative complications as a result of the use of B&O suppository, including urinary retention.
|
14 days post-op
|
Number of Participants With Unanticipated Postoperative Visits
Time Frame: 14 days post-op
|
Number of postoperative unanticipated visits including nursing visits and ED visits
|
14 days post-op
|
Measurement of Post-operative Narcotic Use
Time Frame: 14 days post-op
|
Measurement of postoperative opiate use using a questionnaire.
We will define success as a reduction in postoperative narcotic use by 10% compared to placebo.
|
14 days post-op
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 44862
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrolithiasis
-
Mayo ClinicCompletedNephrolithiasis, Calcium Oxalate | Nephrolithiasis, Calcium PhosphateUnited States
-
University Hospital Inselspital, BerneCompletedCalcium NephrolithiasisSwitzerland
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnUric Acid NephrolithiasisUnited States
-
University of British ColumbiaRecruiting
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingKidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mahidol UniversityNot yet recruitingSafety Issues | Surgery-Complications | Nephrolithiasis Staghorn CalculusThailand
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Himalaya...CompletedCystinuria | Nephrolithiasis, Calcium OxalateUnited States
-
Ai PengUnknown
Clinical Trials on Belladonna and Opium
-
Campbell GrantTerminatedOveractive BladderUnited States
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterCompleted
-
Kristina A. ButlerCompletedVaginal SurgeryUnited States
-
Anna ReinertUniversity of MarylandCompleted
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la LoireCompleted
-
University of British ColumbiaTehran University of Medical Sciences; AJA University of Medical Sciences; Iran...CompletedOpioid DependenceIran, Islamic Republic of
-
Marathon Pharmaceuticals, LLCWithdrawnShort Bowel Syndrome | Short Gut Syndrome | SBS | Short Gut | Short BowelUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...CompletedBlood Loss, SurgicalCanada
-
Asbjørn Mohr DrewesAarhus University HospitalRecruiting
-
Asbjørn Mohr DrewesCompleted